PNR Ref
 PNR Req
 Blank PNRs
 Spotting
 Timeline
 Travel Tip
 Trip
 Race
 Social
 Greeting
 Poll
 Img
 PNR
 Pic
 Blog
 News
 Conf TL
 RF Club
 Convention
 Monitor
 Topic
 Bookmarks
 Rating
 Correct
 Wrong
 Stamp
 HJ
 Vote
 Pred
 @
 FM Alert
 FM Approval
 Pvt
News Super Search
 ↓ 
×
Member:
Posting Date From:
Posting Date To:
Category:
Zone:
Language:
IR Press Release:

Search
  Go  

Purvanchal Express - Poorvottar ka Sikandar

Full Site Search
  Full Site Search  
 
Sun Nov 29 11:14:09 IST
Home
Trains
ΣChains
Atlas
PNR
Forum
Topics
Gallery
News
FAQ
Trips/Spottings
Login
Advanced Search
<<prev entry    next entry>>
News Entry# 422049
Oct 20 (12:33) Coronavirus vaccine update: China's Sinovac is safe, says Brazil's leading research institute (www.moneycontrol.com)
*covid-19
0 Followers
1618 views

News Entry# 422049  Blog Entry# 4753112   
  Past Edits
This is a new feature showing past edits to this News Post.
São Paulo's Butantan Institute, one of Brazil's leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.



An
...
more...
experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe in a late-stage clinical trial in Brazil, preliminary results showed on Monday.

São Paulo's Butantan Institute, one of Brazil's leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

But Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed on all of the 13,000 volunteers.

COVID-19 Vaccine

Frequently Asked Questions

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

related news

Young and restless: Protest parallels in Thailand and Hong Kong

Canadian town of Asbestos breathes easy with new name

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

"The first results of the clinical study conducted in Brazil prove that among all the vaccines tested in the country, CoronaVac is the safest, the one with the best and most promising rates," São Paulo Governor João Doria told reporters.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The result is only preliminary and researchers will keep monitoring the participants in the on-going trial, Covas said. It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

Covas said there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain from the injection while 15% reported headaches after the first dose, dropping to 10% for the second. Less than 5% reported nausea or tiredness, and even less had muscle aches, he said.

São Paulo state health secretary Jean Gorinchteyn said the vaccine appeared to produce protective anti-bodies. The state hopes to obtain regulatory approval for CoronaVac by the end of the year to start inoculating its population early in 2021, in what could the first vaccination programs in the Americas.

São Paulo signed a deal with Sinovac to buy 60 million doses by the end of February.

Sinovac wanted Brazil as a testing ground because it has been one of the global hotbeds of the virus, although cases are 43% off their peak of nearly 70,000 new cases a day in late July.

Brazil has reported more than 5.2 million COVID-19 cases since the pandemic began, the world's third most-affected country after the United States and India.

AstraZeneca PLC and Oxford University are nearing an analysis of their UK coronavirus vaccine trial. Pfizer Inc has said it could provide an early analysis of its trial this month, and Moderna Inc may announce its results in November. Russia's Gamaleya Institute may provide an analysis of its vaccine in the next month.

Competing candidates developed by AstraZeneca and Johnson & Johnson have had their trials halted in the United States due to safety issues.

Vaccines are considered as essential tools to curb the rampaging virus, which has killed over 1 million people globally. Brazil is also hosting a Phase 3 trial for AstraZeneca's vaccine candidate, while Johnson & Johnson said last month it aims to expand its final-stage human trials there.

CoronaVac uses inactivated vaccine technology, a traditional method that uses killed virus that cannot replicate in human cells to trigger an immune response.

tags #coronavirus #World News

Watch

Must Listen

Coronavirus Essential | Global COVID-19 tally reaches 4 crore; US may buy up Britain's vaccine stock, says report

stay updated

Trending news

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.

Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy